FDA
-
-
-
-
-
-
-
Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Raymond James Starts Taysha Gene Therapies (TSHA) at Strong Buy
-
-
-
-
-
-
-
Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome
-
-
-
-
-
-
-
Taysha Gene Therapies (TSHA) Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult
-
-
-
-
-
-
-
Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Jefferies Assumes Taysha Gene Therapies (TSHA) at Buy
-
-
-
-
-
-
-
Taysha Gene Therapies Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients
-
322,090 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

